The use of KB kinase inhibitors with sulfasalazine as well as interference with small RNA signals micro RNA signals that play important role in fibrogenesis are of particularly great interest as potential activators of apoptosis of HSCs 60-62. 3. Aghemo A, Colombo M. Cirrhosis regression in chronic hepatitis C: an old tale with a new ending. Gastroenterology 2009; 136: 1447-49. 4. Zois CD, Balltayiannis GH, Karayiannis P, Tsianos EV. Systematic review: hepatic fibrosis-regression with therapy. Aliment Pharmacol Ther 2008; 28: 1175-87. 5. McCuskey RS. The hepatic microvascular system in health and its response to toxicants. The Anatomical Record 2008; 291: 661-671. 7. Gressner OA. Weiskirchen R, Gressner AM. Evolving concepts of liver fibrogenesis provide new diagnostic and therapeutics options. Comparative Hepatology 2007; 6: 1-13. 10. Marcos R, Rocha E, Henrique RMF, Monteiro RAF. A new approach to an unbiased estímate of the hepatic stellate cell index in the rat liver: an example in healthy conditions. J Histochem Cytochem 2003; 51: 1101-4. 11. Schoemaker MH, Rots MG, Beljaars L, Ypma AY, Jansen PL, Poelstra K et al. PDGF-receptor beta-targeted adenovirus redirects gene transfer from hepatocytes to activated stellate cells. Mol Pharm. 2008; 53: 399-406. 12. Friedman SL, Roll FJ, Boyles J. Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. Proc Nat Acad Sci USA 1985:82:8681-5. 13. Friedman SL. Hepatic stellate cells: protean multifunctional and enigmatic cells of the liver. Physiol Rev 2008 881: 125-172. 14. Rippe RA. Brenner DA. From quiescence to activation gen regulation in hepatic stellate cells. Gastroenterology 2004; 27:1260-1262. 15. Borkham-Kamphorts E, van Roeyen CR, Ostendorf T, Floege J, Gressner AM, Weiskirchen R, Pro-fibrogenic potential of PDGF in liver fibrosis. J Hepatol 2007; 46:1064-107. 16. Ikeda K, Wakahara T, Wang YQ, Kadoya H, Kawada N, Kaneda K. In vitro migratory potential of rat quiescent hepatic stellate cells and its augmentation by cell activation. Hepatology 1999; 29: 1760-1767. 17. Mezaki Y, Yamaguchi N, Yoshikawa K, Miura M, Imail K, Itoh H, Senoo H. Insoluble, speckled cytosolic distribution of retinoic acid receptor alpha protein as a marker of hepatic stellate cell activation in vitro. J Hystochem Cytochem 2009; 57: 687-699. 18. Hazra S, Xiong S, Wang J, Rippe RA, Krishna V, Chatterjee K, et al. Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells. J Biol Chem 2004; 279:392-401. 19. Gressner OA, Gressner AM. Connective tissue growth factor: a fibrogenic master switch in fibrotic liver diseases. Liver international 2008; 28:1065-79. 20. Muñoz-Luque J, Ros J, Fernandez-Varo G, Tugues S, Morales-Ruiz M, Álvarez CE, Friedman SL, Arroyo V, et al. Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J Pharmacol Exp Ther 2008; 324: 475-483. 21. Soon RK, Feel HF. Stellate cell contraction: role, regulation, and potential therapeutic target. Clin Liver Dis 2008; 12: 791-803. 22. Lee JS, Semela D, Iredale J, Shah VH. Sinusoidal remodelling and angiogenesis: a new function for the liver-specific pericyte? Hepatology 2007; 45: 817-825. 24. aeschke H. Mechanisms of liver injury. Mechanisms of neutrophil-induced liver cell injury during hepatic ischemia-reperfusion and other acute inflammatory conditions. Am J Physiol 2006; 290: G1083-G1088. 25. Iredale JP. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 2007; 117: 539548. 26. Benyon RC, Arthur MJ. Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis 2001; 21: 373384. 27. Han YP, Yan C, Zhou L, Qin L, Tsukamoto H. A matrix metalloproteinase 9 activation cascade by hepatic stellate cells in trans-differentiation in the three-dimensional extracellular matrix. J Biol C 2007; 282: 12.928-12.939. 28. Priya S, Sudhakaran P. Cell survival, activation and apoptosis of hepatic stellate cells: modulation by extracellular matrix proteins. Hepatology research 2008; 38: 1221-1232. 29. Kisseleva T, Brenner D. Stellate Cell Biology. Hepatic stellate cells and the reversal of fibrosis. J Gastroenterol Hepat 2006; 21: S84-S87. 30. Jeon WI, Park O, Gao B. Abrogation of the antifibrotic effects of natural killer cells/interferon-gamma contributes to alcohol acceleration of liver fibrosis. Gastroenterology.2008; 134: 248-258. 34. Andersen EA, Christensen PB, Weis N. Transient elastography for liver fibrosis diagnosis. Eur J Intern Med 2009; 20: 339-42. 35. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD; American Association for the Study of Liver Diseases. Liver biopsy. Hepatology 2009; 49: 1017-1044. 37. Cales P, de Ledinghen V, Halfon P, Bacq Y, Leroy V, Boursier J et al. Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C. Liver Int 2008; 28: 1352-62. 38. Poynard T, Morra R, Halfon P, Castera L, Ratziu V, Imbert-Bismut F, et al. Meta-analisys of Fibro Test diagnostic value in chronic liver disease. BMC Gastroenterol 2007; 7: 40-8. 39. Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol 2007; 102: 2589-2600. 40. Sebastiani G, Halfon P, Castera L, SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology 2009 49: 1821-7 41. Friedrich-Rust M, Ong MF, Martens S, Sarrazin S, Bojunga J, Zeuzem S, et al. .Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134: 960-74. 42. Sandrin L, Fourquet B, Hasquenopoh J, Yon S, Fournier C, Mal F, et al. Transiet elastography: a new noninvasive method for assesment of hepatic fibrosis. Ultra Med Bio 2003; 29: 1705-13. 43. Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124: 105-117. 44. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis inpatients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-1313. 45. Rambaldi A, Gluud C. Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. Cochrane Database Syst Rev 2001; 3: CD002148. 46. Armendáriz-Borunda J, Islas-Carbajal MC, Meza-García E. A pilot study in patients with established advanced liver fibrosis using pirfenidone. Gut 2006; 55: 1663-5 47. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management Hepatology 2009; 49: 306-17. 49. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved non-alcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003; 38: 1008-17. 50. Lutchman G, Modi A, Kleiner DE, Promrat K, Heller T, Ghany M et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 2007; 46: 424-9. 51. Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hatermann-Heurtier A, Serfaty L, et al. LIDO Study Group Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy FLIRT Trial Gastroenterology 2008; 135: 100-10. 52. Kisseleva T, Brenner DA. Role of hepatic stellate cells in fibrogenesis and the reversal of fibrosis. J Gastroenterol Hepatol. 2007; 22 Suppl 1: S73-8. 53. Yoshiji H, Kuriyama S, Fukui H. Blockade of renin-angiotensin system in antifibrotic therapy. J Gastroenterol Hepatol 2007; 22Suppl 1: S93-5. 54. Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K, et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with non-alcoholic steatohepatitis. Hepatology 2004; 40: 1222-5. 55. Terui Y, Saito T, Watanabe H, Togashi H, Kawata S, Kamada Y, et al. Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C. Hepatology 2002; 364 Pt 1: 1022. 56. Sookoian S, Fernández MA, Castaño G. Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: a pilot study. World J Gastroenterol 2005; 11: 7560-3. 57. Pockros PJ, Jeffers L, Afdhal N, Goodman ZD, Nelson D, Gish RG, et al. Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. Hepatology 2007; 45: 569-78. 58. Weng HL, Wang BE, Jia JD, Wu WF, Xian JZ, Mertens PR, et al. Effect of interferon-gamma on hepatic fibrosis in chronic hepatitis B virus infection: a randomized controlled study. Clin Gastroenterol Hepatol 2005; 3: 81928. 59. Luk JM, Wang X, Liu P, Wong KF, Chan Kl, Tong Y, et al. Traditional Chinese herbal medicines for treatment of liver fibrosis and cancer: from laboratory discovery to clinical evaluation. Liver Int 2007; 27: 879-90. 60. Siegmund SV, Schwabe RF. Endocannabinoids and liver disease. II. Endocannabinoids in the pathogenesis and treatment of liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2008; 294: G357-62. 61. Sato Y, Murase K, Kato J, Kobune M, Sato T, Kawano Y, et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnology 2008; 26: 431-42. 62. Oakley F, Meso, M Iredale JP. Inhibition of inhibitor of kappa B kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from liver fibrosis. Gastroenterology 2005; 128: 108-120.
Particularmente reviste gran interés el obtener la apoptosis de CEHs activadas utilizando inhibidores de KB kinasa con sulfasalazina y también la interferencia de las pequeñas señales de RNA micro-RNAs que juegan un papel importante en la fibrogénesis 60-62.